INCY · 10-Q · 2026Q3 · Full report

ATEBRIOZ Mirum Licensing Deal

INCYTE CORP · 2026-10-29 · Importance 43 · Surprise 42

In April 2026, Incyte granted Mirum worldwide rights to ATEBRIOZ (zilurgisertib), receiving an upfront payment and eligibility for development and regulatory milestones, sales milestones and tiered royalties in the mid-to-high single digits. Following the FDA’s September 2026 approval of ATEBRIOZ for FOP, Incyte received a Priority Review Voucher. Under the October 2025 Lilly amendment, Incyte received a $100.0 million upfront payment and became eligible for either fixed or tiered baricitinib royalties, with tiered rates up to the mid-teens; COVID-19 sales continue to carry a royalty premium.

Key facts

• Under the ATEBRIOZ agreement, Incyte received an upfront payment and is eligible for development and regulatory milestones, sales-based milestones, and tiered royalties in the mid-to-high single digit percent range on worldwide net sales. source
• In April 2026, Incyte entered into an exclusive license agreement granting Mirum worldwide rights to ATEBRIOZ (zilurgisertib), an ALK2 inhibitor for FOP. source
• In September 2026, the FDA approved ATEBRIOZ (zilurgisertib) to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with FOP; Incyte received a Priority Review Voucher in connection with the approval. source